
Quarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals Market Cap 2011-2026 | CASI
As of April 06, 2026 CASI Pharmaceuticals has a market cap of $ 35.4 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 B | 371 M | 285 M | 300 M | 255 M | 74.3 M | 35 M | 45.5 M | 49.9 M | 39.6 M | 28.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.09 B | 28.2 M | 234 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Anika Therapeutics
ANIK
|
373 M | $ 14.93 | 0.88 % | $ 219 M | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.93 | 0.51 % | $ 5.07 M | ||
|
Aquestive Therapeutics
AQST
|
467 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 8.39 | 4.5 % | $ 230 M | ||
|
Ardelyx
ARDX
|
1.62 B | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
argenx SE
ARGX
|
13.8 B | $ 749.68 | 0.44 % | $ 25 B | ||
|
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
869 M | $ 11.36 | 4.7 % | $ 805 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 61.99 | 1.57 % | $ 8.29 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Assembly Biosciences
ASMB
|
308 M | $ 29.09 | 0.28 % | $ 326 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Actinium Pharmaceuticals
ATNM
|
30.9 M | $ 1.13 | 15.26 % | $ 35.3 M | ||
|
Atossa Therapeutics
ATOS
|
46.7 M | $ 5.19 | -3.36 % | $ 44.7 M | ||
|
Atara Biotherapeutics
ATRA
|
73.6 M | $ 5.0 | 0.2 % | $ 62.7 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
1.86 B | $ 16.05 | 2.79 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.41 | -0.35 % | $ 375 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Axon Enterprise
AXON
|
39.8 B | $ 411.97 | -0.2 % | $ 31.2 B | ||
|
Aytu BioScience
AYTU
|
15.8 M | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
BioCardia
BCDA
|
8.07 M | $ 1.18 | -1.67 % | $ 7.87 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
1.72 B | $ 9.59 | 6.26 % | $ 1.98 B | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 3.05 | 1.51 % | $ 260 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 9.46 | -3.47 % | $ 612 M | ||
|
BioVie
BIVI
|
2.44 M | $ 1.46 | 2.81 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 56.04 | 0.96 % | $ 10.7 B | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 91.64 | 0.5 % | $ 27.2 B | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
BioXcel Therapeutics
BTAI
|
15.4 M | $ 1.18 | -0.42 % | $ 14.4 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 4.5 | 8.57 % | $ 683 M |